142015-75-6

Usage

General Description

The chemical compound 3-[4-[1-(2-cyano-5-methyl pyrrolyl)]benzyl]-7-methyl-2-propyl-3H-imidazo[4,5-b]pyridine, which has a molecular formula of C26H26N4, is a heterocyclic compound with potential pharmaceutical applications. It contains an imidazo[4,5-b]pyridine core structure and a benzyl group attached to a pyrrolyl moiety. 3-[4-[1-(2-cyano-5-methyl pyrrolyl)]benzyl]-7-methyl-2-propyl-3H-imidazo[4,5-b]pyridine may have potential biological activity due to its structural features, such as the cyano and methyl functional groups. However, specific properties and uses of this chemical are subject to further research and testing.

Upstream product

• 6635-86-5 2-amino-4-methyl-3-nitropyridine 
• 142015-63-2 1-(4-ethoxycarbonylphenyl)-5-methypyrrole-2-carbonitrile 
• 5044-37-1 1-(4-ethoxycarbonylphenyl)pyrrole 
• 94-09-7 p-aminoethylbenzoate 
• 142016-33-9 2-(butyrylamino)-4-methyl-3-nitropyridine 

Downstream Products

• 142014-44-6 7-Methyl-3-[4-[2-methyl-5-(1H-tetrazol-5-yl)-1-pyrrolyl]benzyl]-2-propyl-3H-imidazo[4,5-b]pyridine 

Relevant academic research and scientific papers

Pilot scale synthesis of a novel nonpeptide angiotensin II receptor antagonist

FR143187 is a novel nonpeptide angiotensin II receptor antagonist under development at Fujisawa Pharmaceutical Co. for the treatment of hypertension. Development of a process for preparation on a large scale is described. The optimized process is 10 steps in length and uses only commercially available materials for each step. Efficient methylation of the 2-position of a pyrrole derivative was achieved by reduction of a Mannich base via the quaternary ammonium salt. Selective cyanation directed by a solvent effect was also investigated. Process improvement efforts focused on optimized reaction conditions for each step, leading to a high-quality product according to a new and concise synthetic route.

ANGIOTENSIN II ANTAGONIZING HETEROCYCLIC DERIVATIVES

The invention relates to compounds of the formula STR1 wherein STR2 represents a condensed or uncondensed imidazolyl ring and the rest of the variables are as defined in the specification. They are angiotensin II antagonists useful for treating hypertension, etc..